A Study Measuring Bleeding and Coagulation Function in Patients with Aspirin Exacerbated Respiratory Disease


About this study

The purpose of this study is to learn more about aspirin exacerbated respiratory disease (AERD) by collecting blood samples from affected patients to study bleeding and clotting function.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • High index of suspicion for diagnosis of AERD i.e. Asthma, presence of chronic rhinosinusitis with nasal polyps and history of reaction/intolerance to aspirin or NSAIDS (Non-steroidal anti-inflammatory drugs)
  • Symptom burden suggesting presence of active disease with total SNOT-22 score more than 7 (normal)
  • Evaluation in ENT and/or Allergy Clinic with confirmation of chronic sinusitis and/or nasal polyposis
  • Willingness to undergo blood draw

Exclusion Criteria

  • Has asthma, nasal polyps and lacks a clear history suggestive of ASA sensitivity
  • Well controlled AERD (total SNOT-22 scores <7) 
  • Past history of ASA desensitization with ongoing therapy
  • On 5-LO antagonists (Zileuton)
  • On anti-coagulation
  • On systemic steroids 6 weeks prior to assessment
  • Women of childbearing age who are pregnant

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Erin O'Brien, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer